The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20090043: Toyota Boshoku Corporation; Johnson Controls, Inc.
20090042: Toyota Boshoku Corporation; Toyota Boshoku Corporation
20090028: Icahn Partners Master Fund II LP; The Williams Companies, Inc.
20090027: Carl C. Icahn; The Williams Companies, Inc.
Bacon, Holly A., d/b/a Cleansing Time Pro., In the Matter of
Bioque Technologies, Inc., et al., In the Matter of
Daryl C. Jenks, individually and d/b/a Premium Essiac Tea 4less, In the Matter of
20081693: Wolters Kluwer N.V.; Platform Partners, LLC
Appliance Labeling Rule - 16 CFR Part 305
0810008 Informal Interpretation
20090003: Puget Energy, Inc.; Wayzata Opportunities Fund, LLC
0810007 Informal Interpretation
20090022: Health Care Service Corporation; TMG Health, Inc.
20090031: Oracle Corporation; Primavera Software, Inc.
Fresenius Medical Care AG & Co. KGaA, et al., In the Matter of
The Commission challenged Fresenius Medical Care’s proposed purchase of an exclusive sublicense for the manufacture and supply of the drug Venofer to US dialysis clinics from Daiichi Sankyo Company. Venofer is an intravenously administered iron sucrose preparation used primarily to treat iron-deficiency anemia in dialysis patients with chronic kidney disease. The agreement would have given Fresenius, the largest operator of dialysis clinics in the country, the ability to artificially inflate its internal costs for Venofer, and effectively increase Medicare reimbursement payments for all buyers of the drug. In order to settle these concerns about anticompetitive self-dealing, the Commission issued a consent order restricting Fresenius from reporting internally inflated Venofer prices by mandating that the current market price for the drug be used in reporting the average selling price to Medicare.